• OPEN AN ACCOUNT
Indian Indices
Nifty
24,579.60 -45.45
(-0.18%)
Sensex
80,157.88 -206.61
( -0.26%)
Bank Nifty
53,661.00 -341.45
( -0.63%)
Nifty IT
35,737.90 -2.75
( -0.01%)
Global Indices
Nasdaq
45,565.88 -92.03
(-0.20%)
Dow Jones
6,481.26 -41.60
(-0.64%)
Hang Seng
42,288.11 99.32
(0.24%)
Nikkei 225
9,196.34 9.00
(0.10%)
Forex
USD-INR
88.15 0.55
(0.63%)
EUR-INR
103.00 0.84
(0.82%)
GBP-INR
118.99 0.66
(0.55%)
JPY-INR
0.60 0.00
(0.61%)

EQUITY - MARKET SCREENER

Bajaj Healthcare Ltd
Industry :  Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code
ISIN Demat
Book Value()
539872
INE411U01027
147.5977287
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
BAJAJHCARE
28.49
1341.81
EPS(TTM)
Face Value()
Div & Yield %
14.91
5
0.24
 

Marksans Pharma rises as UK subsidiary gets approval for Metformin Prolonged release tablets
Aug 18,2025
The approval was granted by the UK regulatory authorities, allowing Relonchem to market the widely used anti-diabetic medication in three dosage strengths. Metformin is commonly prescribed for the treatment of type 2 diabetes and is considered a frontline therapy for managing blood glucose levels.

Marksans Pharma is primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulations.

The company’s consolidated net profit dropped 34.3% to Rs 58.31 crore despite of 4.97% jump in revenue from operations to Rs 619.98 crore in Q1 FY26 over Q1 FY25.